Viral Vector
Lentiviral lead vector design is the basis for successful cell therapy development
Lentiviral vectors integrate stably into the genome and are thus a reliable tool for ex vivo gene therapy or cell therapy. Revvity Gene Delivery (formerly SIRION Biotech) offers different technologies to support lentiviral vector development.
for Research Use Only
Lentiviral vector surface modification
Increasing specificity is a key prerequisite for developing safe and effective gene and cell therapies. Our surface modification technology directs lentiviral vectors against a specific molecular target to further improve transduction
Revvity Gene Delivery lentivirus surface modification technology has several advantages:
- Achievement of sufficient genetic modification at low MOIs
- Effective independent of cell type
- Synergistic effect with LentiBOOST(r)
- Ideal for treating otherwise hard to transduce, therapeutically relevant cell types.
Increasing specificity is a key prerequisite for developing safe and effective gene and cell therapies. Our surface modification technology directs lentiviral vectors against a specific molecular target to further improve transduction
Revvity Gene Delivery lentivirus surface modification technology has several advantages:
- Achievement of sufficient genetic modification at low MOIs
- Effective independent of cell type
- Synergistic effect with LentiBOOST(r)
- Ideal for treating otherwise hard to transduce, therapeutically relevant cell types.
Lentiviral vector expression cassette development
Lentiviral vectors feature a high packaging capacity for large and complex transgene cassettes and are an excellent vehicle for CAR and TCR constructs in ex vivo gene therapy development.
To tailor the therapeutic transgene cassette to the CGT developer’s needs, a broad range of strategies and molecular tools is offered, including:
- Physiologic and regulated promoter activity
- Reduction of immunogenicity (e.g. by CpG analysis)
- Tissue specific translation regulation
- Transcriptional and translational regulation of bi- and multicistronic cassettes
Lentiviral vectors feature a high packaging capacity for large and complex transgene cassettes and are an excellent vehicle for CAR and TCR constructs in ex vivo gene therapy development.
To tailor the therapeutic transgene cassette to the CGT developer’s needs, a broad range of strategies and molecular tools is offered, including:
- Physiologic and regulated promoter activity
- Reduction of immunogenicity (e.g. by CpG analysis)
- Tissue specific translation regulation
- Transcriptional and translational regulation of bi- and multicistronic cassettes
Questions?
We’re here to help.
Contact us Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.